• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Benitec Biopharma Inc. (Amendment)

    4/11/24 12:10:36 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNTC alert in real time by email
    SC 13G/A 1 p24-1420sc13ga.htm BENITEC BIOPHARMA INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*, **
     

    Benitec Biopharma Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    08205P209

    (CUSIP Number)
     

    August 11, 2023 and December 31, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    ** This Amendment No. 1 is being filed to amend and restate the original Schedule 13G filed with the Securities and Exchange Commission on August 25, 2023 with respect to the shares of Common Stock held by the Reporting Persons (as defined in Item 2(a) hereof) to include certain shares of Common Stock issuable upon exercise of warrants held by the Reporting Persons on August 11, 2023 and to report the Reporting Persons’ beneficial ownership as of December 31, 2023.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

    CUSIP No. 08205P20913GPage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%*

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    *The information set forth on this cover page reflects information as of December 31, 2023. As of August 11, 2023, the Reporting Persons may have been deemed to beneficially own 266,227 shares of Common Stock (including 143,039 shares of Common Stock issuable upon exercise of warrants), representing 9.99% of the outstanding shares of Common Stock as of such time.

     

     

    CUSIP No. 08205P20913GPage 3 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%*

    12

    TYPE OF REPORTING PERSON

    OO

             

     

    *The information set forth on this cover page reflects information as of December 31, 2023. As of August 11, 2023, the Reporting Persons may have been deemed to beneficially own 266,227 shares of Common Stock (including 143,039 shares of Common Stock issuable upon exercise of warrants), representing 9.99% of the outstanding shares of Common Stock as of such time.

     

    CUSIP No. 08205P20913GPage 4 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%*

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

    *The information set forth on this cover page reflects information as of December 31, 2023. As of August 11, 2023, the Reporting Persons may have been deemed to beneficially own 266,227 shares of Common Stock (including 143,039 shares of Common Stock issuable upon exercise of warrants), representing 9.99% of the outstanding shares of Common Stock as of such time.

     

    CUSIP No. 08205P20913GPage 5 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    *The information set forth on this cover page reflects information as of December 31, 2023. As of August 11, 2023, the Reporting Persons may have been deemed to beneficially own 266,227 shares of Common Stock (including 143,039 shares of Common Stock issuable upon exercise of warrants), representing 9.99% of the outstanding shares of Common Stock as of such time. 

     

    CUSIP No. 08205P20913GPage 6 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    264,510 shares of Common Stock (including 75,322 shares of Common Stock issuable upon exercise of warrants)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    *The information set forth on this cover page reflects information as of December 31, 2023. As of August 11, 2023, the Reporting Persons may have been deemed to beneficially own 266,227 shares of Common Stock (including 143,039 shares of Common Stock issuable upon exercise of warrants), representing 9.99% of the outstanding shares of Common Stock as of such time.

     

     

    CUSIP No. 08205P20913GPage 7 of 10 Pages

      

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Benitec Biopharma Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
      The Company’s principal executive offices are located at 3940 Trust Way, Hayward, California 94545.

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:
       
      (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”) with respect to the Common Stock and shares of Common Stock issuable upon exercise of warrants directly owned by it;
       
      (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), as general partner of ACP with respect to the Common Stock and shares of Common Stock issuable upon exercise of warrants directly owned by ACP;
       
      (iii) Adage Capital Management, L.P., a Delaware limited partnership (“ACM”), as the investment manager of ACP, with respect to the Common Stock and shares of Common Stock issuable upon exercise of warrants directly owned by ACP;
       
      (iv) Robert Atchinson (“Mr. Atchinson”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), managing member of ACPGP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ACPLLC”), general partner of ACM, with respect to the Common Stock and shares of Common Stock issuable upon exercise of warrants directly owned by ACP; and
       
      (v) Phillip Gross (“Mr. Gross”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the Common Stock and shares of Common Stock issuable upon exercise of warrants directly owned by ACP.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACP and ACM are limited partnerships organized under the laws of the State of Delaware.  ACPGP is a limited liability company organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

     

    CUSIP No. 08205P20913GPage 8 of 10 Pages

      

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, par value $0.0001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER
      08205P209

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.

     

    Item 4. OWNERSHIP
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentage set forth in this Schedule 13G/A as of August 11, 2023 is calculated based upon 2,521,900 shares of Common Stock outstanding, as reported in the Company’s Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on August 10, 2023 and in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 11, 2023, after giving effect to the completion of the offering and the partial exercise of the underwriters' over-allotment option, all as described therein, and assumes the exercise of the reported warrants. The percentage set forth in this Schedule 13G/A as of December 31, 2023 is calculated based upon 2,572,434 shares of Common Stock outstanding as of November 7, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 13, 2023, and assumes the exercise of the reported warrants.

     

    CUSIP No. 08205P20913GPage 9 of 10 Pages

     

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 08205P20913GPage 10 of 10 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: April 11, 2024

     

      ADAGE CAPITAL PARTNERS, L.P.
      By:  Adage Capital Partners GP, L.L.C.,
      its general partner
       
      By:  Adage Capital Advisors, L.L.C.,
      its managing member
       
      /s/ Robert Atchinson
      Name:  Robert Atchinson
      Title: Managing Member
       
      ADAGE CAPITAL PARTNERS GP, L.L.C.
      By:  Adage Capital Advisors, L.L.C.,
      its managing member
       
      /s/ Robert Atchinson
      Name:  Robert Atchinson
      Title: Managing Member
       
      ADAGE CAPITAL MANAGEMENT, L.P.
      By: Adage Capital Partners LLC,
      its general partner
       
      /s/ Robert Atchinson
      Name:  Robert Atchinson
      Title: Managing Member
       
      /s/ Robert Atchinson
      ROBERT ATCHINSON, individually
       
      /s/ Phillip Gross
      PHILLIP GROSS, individually

     

    Get the next $BNTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTC

    DatePrice TargetRatingAnalyst
    7/7/2025Buy
    TD Cowen
    12/16/2024$28.00Buy
    H.C. Wainwright
    12/13/2024$30.00Outperform
    Robert W. Baird
    10/16/2024$35.00Outperform
    Oppenheimer
    9/12/2024$17.00Buy
    Guggenheim
    7/22/2024$13.00Outperform
    Leerink Partners
    6/13/2024$30.00Overweight
    Piper Sandler
    2/17/2022$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BNTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Benitec Biopharma

    TD Cowen initiated coverage of Benitec Biopharma with a rating of Buy

    7/7/25 8:17:08 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Benitec Biopharma with a new price target

    H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00

    12/16/24 6:46:22 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Benitec Biopharma with a new price target

    Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00

    12/13/24 7:25:56 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/22/25 7:45:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $19,999,994 worth of shares (1,481,481 units at $13.50) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    11/10/25 9:51:33 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

    • Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint • The first 4 patients enrolled into Cohort 1 have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the month-12 follow-up timepoint demonstrating durable response to BB-301 HAYWARD, Calif., Jan. 11

    1/11/26 8:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

    –Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301– –Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients in Cohort 1 meeting the formal statistical criteria for response to BB-301– –First patient of Cohort 2 successfully treated with BB-301 in Q4 of 2025– –The Company raised approximately $100 million in an oversubscribed public offering of common stock, which is expected to fund advancement of the BB-301 Oculopharyngeal Muscular Dystrophy

    11/14/25 5:00:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

    HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten public offering of 5,930,000 shares of its common stock and a concurrent registered direct offering of 1,481,481 shares of its common stock with long-term investor Suvretta Capital. Each share of common stock is being sold at an offering price of $13.50. In addition, the Company has granted the underwriters a 30-day option to purchase

    11/6/25 12:19:46 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    SEC Filings

    View All

    SEC Form EFFECT filed by Benitec Biopharma Inc.

    EFFECT - Benitec Biopharma Inc. (0001808898) (Filer)

    2/11/26 12:15:29 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Benitec Biopharma Inc.

    S-3 - Benitec Biopharma Inc. (0001808898) (Filer)

    1/30/26 4:02:35 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.

    SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    1/29/26 11:34:07 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mates Sharon

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    1/26/26 4:10:15 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/22/25 7:45:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Leadership Updates

    Live Leadership Updates

    View All

    Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

    HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025. "We are delighted to welcome Dr. Sharon Mates to Benitec's Board of Directors," said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. "Dr. Mates brings exceptional leadership experience in building successful biotechnology c

    11/3/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

    HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

    7/1/24 7:00:00 AM ET
    $BHVN
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Financials

    Live finance-specific insights

    View All

    Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

    Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its full year ended June 30, 2025. The Company has filed its annual report on Form 10-K with the U.S. Securities and Exchange Commi

    9/22/25 4:05:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Releases Third Quarter 2025 Financial Results

    HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its third fiscal quarter ended March 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. "We are profoundly honored to be closely engaged with the OPMD patient community and are thankful for the support of the Subjects and their families as we remain focused on the continued development

    5/14/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

    -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. The Company has filed its

    2/14/25 8:10:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

    SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/18/24 4:36:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/14/24 1:37:20 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care